[15][17] In 1996, Allergan received FDA approval for Alphagan ophthalmic solution for open-angle glaucoma and ocular hypertension.

[23][24] In the spring of 1983, colleagues Allen Chao and David Hsia formed Watson Pharmaceuticals, a drug development in Libertyville, Illinois.

[25] In late fall of 1983, the company moved to Corona, California, and began to develop and manufacture generic pharmaceuticals.

[29] In 2013, Actavis acquired Irish-registered Warner Chilcott for $5 billion and used the transaction to execute a corporate tax inversion to Ireland.

[36][11] On July 7, 2015, the company acquired the rights to the late stage CGRP migraine portfolio of Merck & Co, as well as two experimental drugs for an upfront payment of $250 million.

[45] On April 5, 2016, after the Obama administration announced its plan to ban tax inversions, Pfizer terminated the acquisition and paid Allergan a $150 million breakup fee.

[50] In August 2016, Allergan plc sold its generic drugs business to Teva Pharmaceutical Industries in a $40.5 billion deal[51][52] and announced the acquisition of ForSight VISION5 for more than $95 million.

[53] In September 2016, CEO Saunders announced what he called a social contract to limit prices on the company's medications.

[59][61][62] That same month, the company announced it would acquire Motus Therapeutics, a developer of treatments for gastrointestinal disorders, for $200 million.

[70] On December 12, the company announced the acquisition of Repros Therapeutics, a developer of drugs for reproductive system diseases.

The company manufactures several pharmaceutical products including Botox (botulinum toxin), Juvederm (injectable filler), CoolSculpting (cryolipolysis), Alphagan (brimonidine), Vraylar (cariprazine HCI), Linzess (linaclotide),[1] and Ubrelvy (ubrogepant).